​

Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AXSM Stock Forecast

Axsome Therapeutics (AXSM) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $133.40, with a high of $180.00 and a low of $106.00. This represents a 26.88% increase from the last price of $105.14.

$50 $80 $110 $140 $170 $200 High: $180 Avg: $133.4 Low: $106 Last Closed Price: $105.14

AXSM Stock Rating

Axsome Therapeutics stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (88.24%), 1 Hold (5.88%), 1 Sell (5.88%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 1 1 15 Strong Sell Sell Hold Buy Strong Buy

AXSM Forecast vs Benchmarks

TypeNameUpside
StockAxsome Therapeutics26.88%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-111
Avg Price Target-$135.00$125.00
Last Closing Price$105.14$105.14$105.14
Upside/Downside-28.40%18.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25512---17
Dec, 24512---17
Nov, 24512---17
Oct, 24612---18
Sep, 24612---18
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Yatin SunejaGuggenheim$135.00$99.4935.69%28.40%
Sep 11, 2024Graig SuvannavejhMizuho Securities$106.00$90.5817.02%0.82%
Sep 03, 2024Cerena ChenWells Fargo$140.00$88.8657.55%33.16%
Aug 06, 2024Raghuram SelvarajuH.C. Wainwright$180.00$83.21116.32%71.20%
Aug 06, 2024Jason GerberryBank of America Securities$106.00$83.9326.30%0.82%
Jul 22, 2024Leonid TimashevRBC Capital$131.00$84.8554.39%24.60%
Jun 05, 2024Leonid TimashevRBC Capital$130.00$72.2479.96%23.64%
May 28, 2024David AmsellemPiper Sandler$115.00$75.1952.95%9.38%
Apr 29, 2024Vikram PurohitMorgan Stanley$115.00$74.1455.11%9.38%
Mar 28, 2024Graig SuvannavejhMizuho Securities$109.00$79.1737.68%3.67%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 31, 2024Cantor FitzgeraldOverweightOverweighthold
Dec 31, 2024H.C. WainwrightBuyBuyhold
Dec 31, 2024Wells FargoOutperformOutperformhold
Dec 31, 2024Morgan StanleyNegativeNegativehold
Dec 30, 2024RBC CapitalOutperformOutperformhold
Dec 30, 2024NeedhamBuyBuyhold
Nov 12, 2024GuggenheimBuyBuyhold
Oct 04, 2024Wells FargoBuyBuyhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 09, 2024Wells FargoBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-4 $2 $8 $14 $20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.86$-0.01-----
Avg Forecast$-4.33$-4.26$-5.46$-1.86$3.49$8.94$14.40
High Forecast$-5.22$-4.59$-6.42$-6.84$-1.77$1.68$11.37
Low Forecast$-3.58$-4.09$-4.84$1.33$7.55$15.48$18.28
Surprise %12.24%-99.77%-----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.04M$270.60M-----
Avg Forecast$46.98M$268.30M$384.09M$632.39M$1.02B$1.47B$2.00B
High Forecast$40.70M$265.55M$380.46M$529.02M$1.02B$1.47B$1.67B
Low Forecast$54.34M$269.66M$387.81M$761.98M$1.03B$1.47B$2.41B
Surprise %6.51%0.86%-----

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-197.77M$-239.24M-----
Avg Forecast$-196.81M$-197.28M$-255.63M$-117.53M$130.33M$454.59M$654.27M
High Forecast$-236.92M$-208.57M$-291.63M$-310.79M$-80.59M$76.31M$516.45M
Low Forecast$-162.61M$-186.00M$-219.63M$60.27M$342.78M$703.18M$830.30M
Surprise %0.49%21.27%-----

AXSM Forecast FAQ

Is Axsome Therapeutics stock a buy?

Axsome Therapeutics stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Axsome Therapeutics is a favorable investment for most analysts.

What is Axsome Therapeutics's price target?

Axsome Therapeutics's price target, set by 17 Wall Street analysts, averages $133.4 over the next 12 months. The price target range spans from $106 at the low end to $180 at the high end, suggesting a potential 26.88% change from the previous close price of $105.14.

How does Axsome Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Axsome Therapeutics stock forecast shows a 26.88% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Axsome Therapeutics over the past three months?

  • January 2025: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Axsome Therapeutics’s EPS forecast?

Axsome Therapeutics's average annual EPS forecast for its fiscal year ending in December is -5.46 for 2024, a 54500.00% increase from the reported $-0.01 in 2023. The prediction for 2025 is $-1.86, $3.49 for 2026, $8.94 for 2027, and $14.4 for 2028.

What is Axsome Therapeutics’s revenue forecast?

Axsome Therapeutics's average annual revenue forecast for its fiscal year ending in December is $384.09M for 2024, a 41.94% increase from the reported $270.6M in 2023. The forecast for 2025 is $632.39M, $1.02B for 2026, $1.47B for 2027, and $2B for 2028.

What is Axsome Therapeutics’s net income forecast?

For its fiscal year ending in December, Axsome Therapeutics's average annual net income forecast is $-256M for 2024, reflecting an 6.85% increase from the reported $-239M in 2023. The projection for 2025 is $-118M, $130.33M for 2026, $454.59M for 2027, and $654.27M for 2028.